Asset Impairment Charge, Number of Products Impaired, Not Expected To Achieve Forecasted Operating Results

No definition available.

Name:	prx_AssetImpairmentChargeNumberofProductsImpairedNotExpectedToAchieveForecastedOperatingResults
Namespace Prefix:	prx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	prx_IntangibleAssetsNetExcludingGoodwillLineItems
Namespace Prefix:	prx_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of Abbreviated New Drug Applications Awaiting Regulatory Approval

+ References

No definition available.

+ Details

Name:	prx_NumberOfAbbreviatedNewDrugApplicationsAwaitingRegulatoryApproval
Namespace Prefix:	prx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of Generic Products with Marketing Rights Acquired Through Merger

+ References

No definition available.

+ Details

Name:	prx_NumberOfGenericProductsWithMarketingRightsAcquiredThroughMerger
Namespace Prefix:	prx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

+ Details

Name:	us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name:	us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.

+ References

+ Details

Name:	us-gaap_AssetImpairmentCharges
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Intangible Assets, net (Narrative) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	3 Months Ended		12 Months Ended				12 Months Ended	9 Months Ended		3 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2013 product	Dec. 31, 2013 product	Dec. 31, 2013 IPR&D [Member]	Dec. 31, 2013 Anchen Acquisition [Member]	Sep. 28, 2012 Anchen Acquisition [Member] IPR&D [Member]	Dec. 31, 2013 Anchen Acquisition [Member] IPR&D [Member]	Jun. 30, 2013 Watson/Actavis Merger [Member]	Nov. 06, 2012 Watson/Actavis Divestiture Products [Member] product drug_application	Dec. 31, 2013 Successor [Member] Sky Growth Merger [Member] product	Dec. 31, 2013 Successor [Member] Sky Growth Merger [Member] Sky Growth Merger Developed Product Intangible Assets [Member]	Dec. 31, 2013 Successor [Member] Watson/Actavis Merger [Member]	Nov. 06, 2012 Successor [Member] Watson/Actavis Divestiture Products [Member] product drug_application	Dec. 31, 2013 Successor [Member] Watson/Actavis Divestiture Products [Member]	Sep. 28, 2012 Predecessor [Member]	Sep. 28, 2012 Predecessor [Member] Anchen Acquisition [Member]	Dec. 31, 2012 Selling, General and Administrative Expenses [Member] Successor [Member]	Dec. 31, 2013 Selling, General and Administrative Expenses [Member] Successor [Member]	Sep. 28, 2012 Selling, General and Administrative Expenses [Member] Predecessor [Member]	Dec. 31, 2011 Selling, General and Administrative Expenses [Member] Predecessor [Member]
Intangible Assets, Net (Excluding Goodwill) [Line Items]
Amortization expense related to intangible assets																$ 42,801	$ 184,258	$ 31,196	$ 14,822
Asset impairment charges	$ 39,480		$ 60,147	$ 100,093	$ 2,000	$ 60,147	$ 466				$ 39,946			$ 5,700	$ 3,700
Weighted average amortization period										6 years			7 years
Number of products associated with IPR&D (projects)	5	6							68
Number of generic products with marketing rights acquired through merger (products)								5				5
Number of abbreviated new drug applications awaiting regulatory approval (products)								8				8